GALT - Galectin Therapeutics Announces Commencement of patient enrollment of the adaptively-designed Phase 2b/3 trial of Belapectin in NASH Cirrhosis (Stock Price: 3.04)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.